Comments
Drug major Lupin has received final approval from the US health regulator to market Voriconazole tablets, used for the treatment of fungal infections, in the American market.
“Its US subsidiary, Gavis Pharmaceuticals LLC (collectively Lupin), has received final approval for its Voriconazole Tablets, 50 mg and 200 mg, and Voriconazole Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration (USFDA) to market a generic equivalent of PF Prism CV’s Vfend tablets,” the company said in a BSE filing.
It further said the company shall commence promoting the products in the US shortly.
According to IMS MAT March 2016 sales data, Vfend tablets, 50 mg and 200 mg, had sales of $92.8 million, while Vfend Oral Suspension, 40 mg/ml, had US sales of $15.9 million.
Lupin shares were trading 0.51 per cent down at Rs 1,441.70 on BSE in the afternoon session.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.